Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study, a 39-year-old Japanese woman with severe alopecia areata demonstrated complete hair regrowth after one year using a combination of 0.5% delgocitinib ointment and excimer laser, suggesting potential efficacy and safety compared to conventional treatments.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.